Olaparib given to patients with high-risk, HER2 − early breast cancer and gGRCA-pathogenic or likely pathogenic breast cancer after completion of local treatment was associated with a significantly longer invasive disease-free endurance of patients, according to a phase III trial (NCT02032823) [50]. Here, ERBB2 is linked to breast carcinoma.